[1. Aparicio T et al. Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis. 2014;46(2):97–10410.1016/j.dld.2013.04.01323796552]Search in Google Scholar
[2. Cloyd JM et al. Duodenal adenocarcinoma: Advances in diagnosis and surgical management. World J Gastrointest Surg. 2016;8(3):212–22110.4240/wjgs.v8.i3.212480732227022448]Search in Google Scholar
[3. Ecker BL et al. Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: A propensity score–matched analysis. Cancer. 2016;122: 693–70110.1002/cncr.2984026717303]Search in Google Scholar
[4. Hochsten HS et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol. 2014;25(6): 1172–810.1093/annonc/mdu107420788124608198]Search in Google Scholar
[5. Lech G et al. Primary small bowel adenocarcinoma: current view on clinical features, risk and prognostic factors, treatment and outcome. Scand J Gastroenterol. 2017;52(11):1194–120210.1080/00365521.2017.135693228737049]Search in Google Scholar
[6. Zhang CD et al. Modified vs. standard D2 lymphadenectomy in distal subtotal gastrectomy for locally advanced gastric cancer patients under 70 years of age. Oncol Lett. 2018;15(1):375–385]Search in Google Scholar
